Evidence map›Paper›PMID 42539570›Full record

ArticleFrontiers in immunology2026

Case Report: Schwann cell reprogramming and PDGF-driven nerve hypertrophy in an NF1 patient with CIDP-like autoimmunity.

Fei Wang, Wenqian Cao, Jiaye Lu, Run Huang, Yuhan Bai, Yining Zhang, Zilan Wang, Zhouqing Chen, Zhong Wang

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fei Wang *Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Wenqian Cao *Suzhou Medical College of Soochow University, Suzhou, Jiangsu, China.
Jiaye LuDepartment of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Run HuangSuzhou Medical College of Soochow University, Suzhou, Jiangsu, China.
Yuhan BaiSuzhou Medical College of Soochow University, Suzhou, Jiangsu, China.
Yining ZhangSuzhou Medical College of Soochow University, Suzhou, Jiangsu, China.
Zilan WangDepartment of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Zhouqing ChenDepartment of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Zhong WangDepartment of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Differentiating neoplastic proliferation from inflammatory fibrosis in peripheral nerve hypertrophy is critical. We report a patient with a neurofibromatosis type 1 (NF1) deletion exhibiting extreme diffuse nerve enlargement and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)-like autoimmunity. This study aims to elucidate the underlying endoneurial fibrotic mechanism, specifically focusing on the signaling networks between Schwann cells (SCs) and fibroblasts. Methods: Single-cell RNA sequencing was performed on a biopsied sural nerve to profile the cellular and transcriptomic landscape. Intercellular interactome and pseudotime trajectory analyses were utilized to map molecular evolution and signaling crosstalk. Results: Transcriptomic profiling revealed that SCs-which normally maintain myelin around axons and support peripheral nerve function-were pathologically entrapped in a dedifferentiated state. Serving as a genetic primer, the Interpretation: Our data suggest that the macroscopic hypertrophic changes observed in this specific clinical presentation may reflect an aberrant, immune-triggered fibrotic cascade-where autoimmune leukocyte infiltration continuously drives stromal overgrowth-complementing rather than entirely precluding the classical RAS/MAPK-driven neoplastic SC hyperproliferation. Furthermore, within the limitations of this pilot evaluation, characterizing this potential SC-fibroblast crosstalk indicates that the PDGF signaling pathway may warrant further investigation as a candidate translational therapeutic target for refractory hypertrophic neuropathies.

Indexed as

AutoimmunityCellular ReprogrammingNeurofibromatosis 1Platelet-Derived Growth FactorPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingSchwann CellsFibroblastsHumansHypertrophyNeurofibromin 1Signal TransductionNeurofibromin 1NF1 protein, humanPlatelet-Derived Growth Factorchronic inflammatory demyelinating polyradiculoneuropathy (CIDP)hypertrophic neuropathyneurofibromatosis type (NF1)PDGF signaling pathwaySchwann cell plasticitysingle-cell transcriptomics

Identifiers

PMID42539570
PMCPMC13424072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.